Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Harrow, Inc. - Common Stock (NQ: HROW )

30.42 -1.49 (-4.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 5/1
Via Investor Brand Network
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
From Harrow
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/21
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 4/4
Via Investor Brand Network
Harrow Health Inc. (NASDAQ: HROW) Climbs to New 52-Week High
Via Investor Brand Network
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
From Harrow
Via Business Wire
Harrow Health Inc. (NASDAQ: HROW) is a Stock Spotlight on 3/22
Via Investor Brand Network
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
From Harrow
Via Business Wire
Earnings Outlook For Harrow Health
Via Benzinga
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
From Harrow
Via Business Wire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow Health, Inc. (NASDAQ:HROW) Shareholder Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- Harrow Health, Inc. is under investigation over potential securities laws in connection with certain financial statements. 
Via SBWire
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
From Harrow
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
From Harrow
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
From The Rosen Law Firm, P.A.
Via Business Wire
Harrow Launches Next-Generation Compounded Atropine Formulations
From Harrow
Via Business Wire
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
From Harrow
Via Business Wire
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
From Harrow
Via Business Wire
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
From Harrow Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.